Emerging Therapeutic Strategies in Oral Cancer: Epigenetic, Mitochondrial and Immunotherapy Approaches
Journal of Cellular and Molecular Medicine · 2026-04 · 30 (8)
DOI: 10.1111/jcmm.71107 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 24.04.2026. Verfasst von Geetha Shanmugam und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai, T…. Hauptthemen laut MEDLINE: Mouth Neoplasms, Mitochondria, Epigenesis, Genetic, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Oral squamous cell carcinoma (OSCC) is the most common type of oral cancer and poses treatment challenges owing to genetic, epigenetic and environmental factors. Conventional treatments, including surgery, chemotherapy and radiation therapy, often have limitations in terms of efficacy and tolerability. Advances in epigenetic therapies such as DNA methyltransferase and histone deacetylase inhibitors offer promising avenues for reversing abnormal gene expression in OSCC. Mitochondria‐targeted therapies leverage metabolic disruption and reactive oxygen species modulation to induce apoptosis. Immunotherapy, particularly with immune checkpoint inhibitors and cancer vaccines, enhances the immune response against cancer cells. This review explores the interplay between the tumour microenvironment and oral microbiome in OSCC progression and treatment response. Additionally, RNA interference therapy and nanoparticle‐based drug delivery systems enable targeted therapeutic strategies, reduce off‐target effects and improve efficacy. Although these approaches show potential, challenges in clinical translation remain. The integration of precision medicine with innovative drug delivery systems can significantly improve patient outcomes in oral cancer management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Global Health Research, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai, Tamil Nadu, India.
- Microbiology and Nanoscience Lab-Helix Research Studio, Department of Neonatology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences, Thandalam, Chennai, Tamil Nadu, India.
- Department of Applied Bioscience, College of Life and Environmental Science, Konkuk University, Seoul, Republic of Korea.
- Centre for Research Impact & Outcome, Chitkara University, Rajpura, Punjab, India.
- Saints Petersburg State Agrarian University, Saints Petersburg, Russia.
- Department of Biological Sciences, College of Science, University of Jeddah, Jeddah, Kingdom of Saudi Arabia.
ORCID-Profile: Rashad Saleh
Zitieren
APA
Shanmugam, G., Singh, C. D., Thiruvengadam, R., Thiruvengadam, M., Morozov, V., Kolesnikov, R., Alkaladi, A., Saleh, R., & Shariati, M. A. (2026). Emerging Therapeutic Strategies in Oral Cancer: Epigenetic, Mitochondrial and Immunotherapy Approaches. Journal of Cellular and Molecular Medicine, 30(8). https://doi.org/10.1111/jcmm.71107
Vancouver
Shanmugam G, Singh CD, Thiruvengadam R, Thiruvengadam M, Morozov V, Kolesnikov R, et al. Emerging Therapeutic Strategies in Oral Cancer: Epigenetic, Mitochondrial and Immunotherapy Approaches. Journal of Cellular and Molecular Medicine. 2026;30(8). doi:10.1111/jcmm.71107
BibTeX
@article{Shanmugam2026,
author = {Shanmugam, Geetha and Singh, Carmelin Durai and Thiruvengadam, Rekha and Thiruvengadam, Muthu and Morozov, Vitaly and Kolesnikov, Roman and Alkaladi, Ali and Saleh, Rashad and Shariati, Mohammad Ali},
title = {Emerging Therapeutic Strategies in Oral Cancer: Epigenetic, Mitochondrial and Immunotherapy Approaches},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {8},
doi = {10.1111/jcmm.71107}
}
EUVIMED